Multi-Modal Anesthesia Protocol in Pain Management of Patients Undergoing Posterior Lumbar Spinal Fusion Surgery

Efficiency of Multi-Modal Anesthesia (MMA) Protocol in Pain Control and Analgesia in Patients Undergoing Posterior Lumbar Spinal Fusion Surgery

This study consisted of a randomized controlled trial designed to evaluate a Multimodal Analgesia (MMA) Protocol on patients undergoing Posterior Spinal Fusion. The purpose is to describe the narcotic requirements and usage during the perioperative period of posterior spinal fusion and instrumentation surgery with the implementation of multimodal anesthesia protocol. The study will consist of two parallel arms, with Group 1 receiving our MMA protocol and Group 2 receiving a traditional opioid-based regime. The primary outcome of this study will be the reported Visual Analog Scale (VAS) for pain at 12, 24, and 48 hours after surgery. We considered that our findings could contribute to the fight against the opioid crisis proving alternatives to opioids as feasible alternatives for pain management even in significant surgery, as is posterior spinal fusion with instrumentation.

Study Overview

• Status: Completed
• Conditions: Pain Management; Posterior Spinal Fusion
• Intervention / Treatment: Drug: Toradol; Drug: Orphenadrine; Drug: Gabapentin; Drug: Acetaminophen; Drug: Bupivacaine; Drug: Epinephrine; Drug: Xylocaine Injectable Solution; Drug: Methylprednisolone; Drug: Morphine

Detailed Description

After seeking Institutional Review Board (IRB) approval, a randomized clinical trial study will be conducted with a diagnosis of Lumbar stenosis between levels of L1-S1 who underwent operative posterior spinal fusion and instrumentation (PSF) and were admitted to Hospital Universitario de Adultos, San Juan, PR. A sample size of n=50 is considered for each study arm. Three surgeons with Spine orthopedic surgery fellowship will perform all the surgical procedures. Inclusion criteria for eligible patients are lumbar stenosis with levels between L1-S1, no prior surgical treatment of spinal deformity, 30 - 85-years of age, and atraumatic pathology. The patients were considered participants after providing written informed consent. Patients were excluded if they were younger than 30 years old or older than 85 years and had a prior history of chronic opioid abuse, corrective surgery, or traumatic pathology. Patients were divided into two randomly selected groups. A random numerator generator has chosen patients' analgesic protocol, creating two groups in an aleatory manner. Group 1 received a Multimodal Analgesia (MMA) Protocol. Group 2 experienced a traditional analgesia protocol (Narcotics/Opioids). As part of the preoperative care for all patients undergoing PSF, lab work includes complete blood count, complete metabolic panel, and coagulation panel. In addition, all patients were assessed by internal medicine for clearance before surgery. Group 1 received multimodal analgesia, including Toradol 60mg IV, Acetaminophen 1,000mg PO, Orphenadrine 100mg PO, and Gabapentin 800 mg PO prior to surgery. Group 2 will not be given oral analgesia preoperatively. As part of the intraoperative care, group 1 was given: Bupivacaine 30cc, Epinephrine 1c,c, and MPF Intramuscular Inj 0.5% (30cc of Saline Solution) in paraspinal and adjacent areas before surgical incision at the time of timeout. Both study arms received routine postoperative care and were followed daily while admitted to the hospital. Patients in group 1 were treated with a postoperative pain management protocol including Gabapentin 300mg PO Q6hrs, Toradol 30mg IV Q6hrs, Methylprednisolone 125mg Q8hrs, and orphenadrine 100mg PO twice daily. Group 2 received a traditional opioid-based pain management approach with Morphine 4mg Q4hrs. Patients were asked for daily pain levels using 1-10, and IV morphine use as needed will be measured daily. Data Collection will occur intra-hospital during the perioperative period. The study variables retrieved included sociodemographic Information, surgery Duration, surgical approach, levels of instrumentation, type of instrumentation, Surgery blood loss, Complications, Discharge Time, Length of Stay, Comorbidities, and Visual Analog Scale (VAS) for pain score preoperative and postoperative at 12, 24, and 48 hours.

• Study Type: Interventional
• Enrollment (Actual): 100
• Phase: Phase 4

Contacts and Locations

Study Locations

• Puerto Rico
  • San Juan, Puerto Rico
    • Puerto Rico Medical Center - University District Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years to 85 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• lumbar stenosis affecting L1-S1
• Requiring Posterior Spinal Fusion Surgery
• Age 30-85 years

Exclusion Criteria:

• younger than 30 years old or older than 85 years
• Chronic Renal Disease
• Hypersensitivity to any medication
• history of chronic opioid abuse.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: SUPPORTIVE_CARE
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: SINGLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: MMA Protocol Group; Preoperative Medications; Orphenadrine 100mg PO once preop; Gabapentin 800mg PO once preop; Toradol 60mg IV once preop; Acetaminophen 1,000mg PO once preop Intraoperative Paraspinal Infusion; Bupivacaine 30cc; Epinephrine 1cc; Xylocaine-MPF Intramuscular Inj 0.5% (30cc of Saline Solution) Postoperative Medications; Orphenadrine 100mg PO BID; Gabapentin 300mg PO Q6; Toradol 30mg IV Q6hrs*; Methylprednisolone 125mg Q8hrs	Drug: Toradol; Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.; Other Names: Multimodal Analgesia Protocol; Drug: Orphenadrine; Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.; Other Names: Multimodal Analgesia Protocol; Drug: Gabapentin; Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.; Other Names: Multimodal Analgesia Protocol; Drug: Acetaminophen; Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.; Other Names: Multimodal Analgesia Protocol; Drug: Bupivacaine; Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.; Other Names: Multimodal Analgesia Protocol; Drug: Epinephrine; Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.; Other Names: Multimodal Analgesia Protocol; Drug: Xylocaine Injectable Solution; Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.; Other Names: Multimodal Analgesia Protocol; Drug: Methylprednisolone; Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.; Other Names: Multimodal Analgesia Protocol
ACTIVE_COMPARATOR: Control (opioids) Group; Postoperative Medication 1-Morphine 4mg Q4hrs	Drug: Morphine; Provide the standard postoperative morphine dose for pain management as part of the traditional opioid-based pain management regime.; Other Names: Opioids; Narcotics

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Visual Analog Scale reported pain score	The numeric rating scale is an 11-point scale scored from 0-10 to describe the intensity of pain. Patients verbally select the numeric value that is more consistent with the pain experienced. The value 0 consist of no pain and 10 consist the worst pain experienced in life. Therefore, the higher the value the worst the pain is considered.	At 12 hours, at 24 hours and at 48 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Days in Hospital	The number of days in hospital represents the duration of postoperative hospital care from the surgery to discharge.	At discharge, at day 3 on average.
Rate of Surgical Complications	The rate of surgical complications will represent any situation that deviates from the adequate/optimal postoperative history or care until discharge.	At discharge, at day 3 on average

Collaborators and Investigators

• Sponsor: University of Puerto Rico
• Investigators: Principal Investigator: José Montañez, MD, Department of Orthopaedic Surgery, University of Puerto Rico, Medical Sciences Campus, San Juan, PR

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 5, 2021
• Primary Completion (ACTUAL): January 28, 2022
• Study Completion (ACTUAL): March 23, 2022

Study Registration Dates

• First Submitted: May 5, 2022
• First Submitted That Met QC Criteria: June 8, 2022
• First Posted (ACTUAL): June 10, 2022

Study Record Updates

• Last Update Posted (ACTUAL): June 10, 2022
• Last Update Submitted That Met QC Criteria: June 8, 2022
• Last Verified: June 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Anti-Arrhythmia Agents; Central Nervous System Depressants; Parasympatholytics; Autonomic Agents; Peripheral Nervous System Agents; Muscarinic Antagonists; Cholinergic Antagonists; Cholinergic Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anesthetics; Excitatory Amino Acid Antagonists; Excitatory Amino Acid Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Cyclooxygenase Inhibitors; Antipyretics; Antiemetics; Gastrointestinal Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Neuroprotective Agents; Protective Agents; Adrenergic alpha-Agonists; Adrenergic Agonists; Analgesics, Opioid; Tranquilizing Agents; Psychotropic Drugs; Membrane Transport Modulators; Anti-Anxiety Agents; Cytochrome P-450 Enzyme Inhibitors; Anticonvulsants; Anesthetics, Local; Voltage-Gated Sodium Channel Blockers; Sodium Channel Blockers; Antimanic Agents; Bronchodilator Agents; Anti-Asthmatic Agents; Respiratory System Agents; Neuromuscular Agents; Adrenergic beta-Agonists; Sympathomimetics; Vasoconstrictor Agents; Muscle Relaxants, Central; Antiparkinson Agents; Anti-Dyskinesia Agents; Mydriatics; Cytochrome P-450 CYP2B6 Inhibitors; Methylprednisolone; Lidocaine; Gabapentin; Acetaminophen; Bupivacaine; Morphine; Epinephrine; Orphenadrine; Ketorolac Tromethamine; Narcotics
• Other Study ID Numbers: A9630120

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: There is no plan to make individual participant data (IPD) available to other researchers. However, data could be shared upon individual researchers' reasonable request.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes